Google Scholar link: https://scholar.google.com/citations?user=FsmAcE4AAAAJ&hl=en

Scientific articles:

1. Park DH, Bhojnagarwala PS, Liaw K, Bordoloi D, Tursi NJ, Zhao S, Binder ZA, O'Rourke D, Weiner DB. Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. J Immunother Cancer. 2024 Dec 2;12(12):e009604 [Selected as highlighted article].

2. O'Connell RP, Liaw K, Wellhausen N, Chuckran CA, Bhojnagarwala PS, Bordoloi D, Park D, Shupin N, Kulp D, June CH, Weiner D. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. J Immunother Cancer. 2024;12(6):e008733.

3. Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, Ionescu C, Perales-Puchalt A, Parzych EM, Zhu X, Ali AR, Cassel J, Zhang R, Betts MR, Abdel-Mohsen M, Weiner DB. Siglec-7 glyco-immune binding MAbs and NK cell engager biologics induce potent anti-tumor immunity against ovarian cancers. Science Advances. 2023; 9(44): eadh4379. 

4. Park DH, Perales-Puchalt A, Liaw K, Bhojnagarwala P, Zhu X, Choi J, Ali AR, Bordoloi D, Gary EN, O’Connell RP, Patel A, Weiner DB. Co-treatment of DNA-encoded bispecific T cell engagers (DBTEs) targeting EGFRvIII and HER2 elicits enhanced tumor control and reduced tumor antigen escape in an animal model of heterogeneous GBM. Molecular therapy-Oncolytics. 2023; 28: 249-263. 

5.  Saini P, Adeniji SO, Bordoloi D, Kinslow J, Martinson J, Parent DM, Hong KY, Koshy J, Kulkarni AJ, Zilberstein NF, Balk RA, Moy JN, Giron LB, Tracy RP, Keshavarzian A, Muthumani K, Landay A, Weiner DB, Abdel-Mohsen M. Siglec-9 Restrains Antibody-dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2. mBio. 2023; 14 (1): e0339322. 

6. Bordoloi D, Bhojnagarwala P, Perales-Puchalt A, Kulkarni AJ, Zhu X, Liaw K, O’Connell RP, Park DH, Kulp DW, Zhang R, Weiner DB. A mAb against surface expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. JCI Insight. 2022;7(21):e162553.  [The article received special editorial highlight].

7. Bhojnagarwala P, O'Connell RP, Park D, Liaw K, Ali AR, Bordoloi D, Tursi NJ, Gary EN, Weiner DB. in vivo DNA launched Bispecific T cell engager (dBTE) targeting IL13Rα2 controls tumor growth in an animal model of Glioblastoma Multiforme. Molecular therapy-Oncolytics. 2022; 26: 289-301. 

8. Bordoloi D*, Harsha C, Padmavathi G, Banik K, Sailo BL, Roy NK, Girisa S, Thakur KK, Khwairakpam AD, Chinnathambi A, Alahmadi TA, Alharbi SA, Shakibaei M, Kunnumakkara AB. Loss of TIPE3 reduced the proliferation, survival and migration of lung cancer cells through inactivation of Akt/mTOR, NF-κB, and STAT-3 signaling cascades. Life Sci. 2022; 293:120332. 

9. Bordoloi D, Xiao P, Choi H, Ho M, Perales-Puchalt A, Khoshnejad M, Kim JJ, Humeau L, Srinivasan A, Weiner DB, Muthumani K. Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens. Genes Cancer. 2021; 12:51-64. 

10. Bordoloi D*, Padmavathi G, Banik K, Devi KA, Harsha C, Girisa S, Buhrmann C, Shakibaei M, Kunnumakkara AB. Human tumor necrosis factor alpha-induced protein eight-like 1 exhibited potent anti-tumor effect through modulation of proliferation, survival, migration and invasion of lung cancer cells. Mol Cell Biochem. 2021; 476(9):3303-3318. (*Corresponding author) 

11. Bordoloi D, Xu Z, Ho M, Bhojnagarwala P, Purwar M, Cassel J, Giron LB, Walker S, Ruiz ET, Zaidi FI, Wu Y, Wang S, Patel A, Ramos S, Smith T, Kulp D, Ugen KE, Srinivasan A, Abdel-Mohsen M, Humeau L, Weiner DB, Muthumani K. Identification of novel neutralizing monoclonal antibodies against SARS-CoV-2 Spike glycoprotein. ACS Pharmacol Transl Sci. 2021; 4(4):1349-1361. [Selected for a Plenary Talk at ACS annual meeting 2021].

12. Zhu X, Perales-Puchalt A, Wojtak K, Xu Z, Yun K, Bhojnagarwala PS, Bordoloi D, Park DH, Liaw K, Bah MA, Lieberman PM, Gary EN, Patel A, Weiner DB. DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas. Mol Ther Oncolytics. 2021; 24:218-229. 

13. Choi H, Ho M, Adeniji OS, Giron L, Bordoloi D, Kulkarni AJ, Puchalt AP, Abdel-Mohsen M, Muthumani K. Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity. Front Oncol. 2021; 11:778989. 

14. Mahalingam S, Peter J, Xu Z, Bordoloi D, Ho M, Kalyanaraman VS, Srinivasan A, Muthumani K. Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon. 2021;7(4):e06836. 

15. Padmavathi G, Monisha J, Bordoloi D, Banik K, Roy NK, Girisa S, Singh AK, Longkumer I, Baruah MN, Kunnumakkara AB. Tumor necrosis factor-α induced protein 8 (TNFAIP8/TIPE) family is differentially expressed in oral cancer and regulates tumorigenesis through Akt/mTOR/STAT3 signaling cascade. Life Sci. 2021; 287:120118. 

16. Bordoloi D*, Banik K, Vikkurthi R, Thakur KK, Padmavathi G, Sailo BL, Girisa S, Chinnathambi A, Alahmadi TA, Alharbi SA, Buhrmann C, Shakibaei M, Kunnumakkara AB. Inflection of Akt/mTOR/STAT-3 cascade in TNF-α induced protein 8 mediated human lung carcinogenesis. Life Sci. 2020; 262:118475. (*Corresponding author) 

17. Choi H, Kudchodkar SB, Ho M, Reuschel EL, Reynolds E, Xu Z, Bordoloi D, Ugen KE, Tebas P, Kim J, Abdel-Mohsen M, Thangamani S, Weiner DB, Muthumani K. A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. PLoS Negl Trop Dis. 2020;14(10):e0008788. 

18. Singh AK, Roy NK, Bordoloi D, Padmavathi G, Banik K, Khwairakpam AD, Kunnumakkara AB, Sukumar P. Orai-1 and Orai-2 regulate oral cancer cell migration and colonisation by suppressing Akt/mTOR/NF-κB signalling. Life Sci. 2020; 261:118372. 

19. Bordoloi D, Banik K, Padmavathi G, Vikkurthi R, Chaudhary H, Roy NK, Singh AK, Javadi M, Wang H, Kumar AP, Kunnumakkara AB. TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-κB Signaling Cascade. Biomolecules. 2019; 9(12):836. 

20. Bordoloi D, Monisha J, Roy NK, Padmavathi G, Banik K, Harsha C, Wang H, Kumar AP, Arfuso F, Kunnumakkara AB. An Investigation on the Therapeutic Potential of Butein, A Tretrahydroxychalcone Against Human Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2019; 20(11):3437-3446.

21. Dharmalingam K, Bordoloi D, Kunnumakkara AB, Anandalakshmi R. Preparation and characterization of cellulose‐based nanocomposite hydrogel films containing CuO/Cu2O/Cu with antibacterial activity. J. Appl. Polym. Sci. 2020; 137 (40): 49216. 

22. Dharmalingam K, Bordoloi D, Kunnumakkara AB, Anandalakshmi R. Formation and characterization of zinc oxide complexes in composite hydrogel films for potential wound healing applications. Polym. Compos. 2020; 41(6): 2274-2287. 

23. Devi Khwairakpam A, Monisha J, Roy NK, Bordoloi D, Padmavathi G, Banik K, Khatoon E Kunnumakkara AB. Vietnamese coriander inhibits cell proliferation, survival and migration via suppression of Akt/mTOR pathway in oral squamous cell carcinoma. J Basic Clin Physiol Pharmacol. 2020 ;31(3). 

24. Roy NK, Monisha J, Padmavathi G, Lalhruaitluanga H, Kumar NS, Singh A, Bordoloi D, Boruah MN, Ahmed GN, Longkumar I, Arfuso F, Kumar AP, Kunnumakkara AB. Isoform-specific role of Akt in oral squamous cell carcinoma. Biomolecules. 2019; 9(7), 253.

25. Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA, Alharbi SA, Sethi G, Kumar AP, Kunnumakkara AB. NGAL is Downregulated in oral Squamous cell Carcinoma and leads to increased survival, proliferation, migration and chemoresistance. Cancers (Basel). 2018;10(7). pii: E228.

26. Girisa S, Saikia Q, Bordoloi D, Banik K, Monisha J, Daimary UD, Verma E, Ahn KS, Kunnumakkara AB. Xanthohumol from Hop: Hope for cancer prevention and treatment. IUBMB Life. 2021; 73(8):1016-1044. 

27. Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, Padmavathi G, Shakibaei M, Sethi G, Kunnumakkara AB. An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases. Int J Mol Sci. 2019; 20(17):4101. 

28. Kunnumakkara AB, Harsha C, Banik K, Vikkurthi R, Sailo BL, Bordoloi D, Gupta Sc, Aggarwal BB. Is curcumin bioavailability a problem in humans: lessons from clinical trials. Expert Opin Drug Metab Toxicol. 2019;15(9):705‐733. 

29. Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, Shakibaei M, Gupta SC, Aggarwal BB. Cancer Drug Development: The Missing Links. Exp Biol Med (Maywood). 2019;244(8):663-689. 

30. Banik K, Ranaware AM, Deshpande V, Bordoloi D, Nalawade SP, Padmavathi G, Sailo BL, Shanmugam MK, Fan L, Arfuso F, Kunnumakkara AB. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019;144:192-209.

31. Sailo BL, Banik K, Girisa S, Bordoloi D, Fan L, Halim CE, Wang H, Kumar AP, Zheng D, Mao X, Sethi G, Kunnumakkara AB. FBXW7 in Cancer: What Has Been Unraveled Thus Far? Cancers (Basel). 2019;11(2): E246. 

32. Bordoloi D, Banik K, Shabnam B, Padmavathi G, Monisha J, Arfuso F, Dharmarajan A, Mao X, Lim LHK, Wang L, Fan L, Hui KM, Kumar AP, Sethi G, Kunnumakkara AB. TIPE family of proteins and its implications in different chronic diseases. Int J Mol Sci. 2018;19(10). pii: E2974. 

33. Padmavathi G, Banik K, Monisha J, Bordoloi D, Shabnam B, Arfuso F, Sethi G, Fan L, Kunnumakkara AB. Novel tumor necrosis factor-α induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression. Cancer Lett. 2018; 432:260-271. 

34. Kunnumakkara AB, Banik K, Bordoloi D, Harsha C, Sailo BL, Padmavathi G, Roy NK, Gupta SC, Aggarwal BB. Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases. Front Pharmacol. 2018; 9:686. 

35. Khwairakpam AD, Bordoloi D, Thakur KK, Monisha J, Arfuso F, Sethi G, Mishra S, Kumar AP, Kunnumakkara AB. Possible use of Punica granatum (Pomegranate) in cancer therapy. Pharmacol Res. 2018; 133:53-64. 

36. Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D, Kunnumakkara AB. Tocotrienols: The promising analogues of vitamin E for cancer therapeutics. Pharmacol Res. 2018;130: 259-272. 

37. Banik K, Harsha C, Bordoloi D, Lalduhsaki Sailo B, Sethi G, Leong HC, Arfuso F, Mishra S, Wang L, Kumar AP, Kunnumakkara AB. Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. Cancer Lett. 2018; 416:75-86.

38. Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming Burden of Triple-Negative Breast Cancer in India. Clin Breast Cancer. 2018; 18(3):e393-e399. 

39. Kunnumakkara AB, Bordoloi D, Harsha C, Banik K, Gupta SC, Aggarwal BB. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci. 2017; 131(15): 1781-1799. 

40. Harsha C, Banik K, Bordoloi D, Kunnumakkara AB. Antiulcer properties of fruits and vegetables: A mechanism based perspective. Food and Chemical Toxicology. 2017; 108(PtA):104-119.

41. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017; 174(11):1325-1348. 

42. Padmavathi G, Roy NK, Bordoloi D, Arfuso F, Mishra S, Sethi G, Bishayee A, Kunnumakkara AB. Butein in health and disease: A comprehensive review. Phytomedicine. 2017; 15 (25):118-127. 

43. Roy NK, Bordoloi D, Monisha J, Padmavathi G, Kotoky J, Golla R, Kunnumakkara AB. Specific Targeting of Akt kinase isoforms: Taking the precise path for prevention and treatment of cancer. Curr Drug Targets. 2017; 18(4):421-435.

44. Monisha J, Roy NK, Bordoloi D, Kumar A, Golla R, Kotoky J, Padmavathi G, Kunnumakkara AB. Nuclear factor kappa B: A potential target to persecute head and neck cancer. Curr Drug Targets. 2017; 18(2):232-253.

45. Bordoloi D, Roy NK, Monisha J, Padmavathi G, Kunnumakkara AB. Multi-targeted agents in cancer cell chemosensitization: What we learnt from curcumin thus far.  Recent Pat Anticancer Drug Discov. 2016; 11(1):67-97. 

46. Monisha J, Padmavathi G, Roy NK, Deka A, Bordoloi D, Anip A, Kunnumakkara AB. NF-κB blockers gifted by Mother Nature: prospectives in cancer cell chemosensitization. Curr Pharm Des. 2016; 22(27):4173-200. 

47. Roy NK, Deka A, Bordoloi D, Mishra S, Kumar AP, Sethi G, Kunnumakkara AB. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett. 2016; 377(1):74-86. 

48. Padmavathi G, Rathnakaram SR, Monisha J, Bordoloi D, Roy NK, Kunnumakkara AB. Potential of butein, a tetrahydroxychalcone to obliterate cancer.  Phytomedicine. 2015; 22(13):1163-71. 

49. Usha B, Bordoloi D, Parida A. Diverse expression of sucrose transporter gene family in Zea mays. J Genet. 2015; 94(1):151-4. 

50. Monisha J, Padmavathi G, Bordoloi D, Roy NK, Kunnumakkara AB. Neutrophil Gelatinase-Associated Lipocalin (NGAL): A promising biomarker for cancer diagnosis and a potential target for cancer therapeutics. Journal of Cell Science & Molecular Biology. 2014; 1(2):106. 

Book:

Cancer Cell Chemoresistance and Chemosensitization, edited by Kunnumakkara AB, Bordoloi D, Monisha J, Publisher: World Scientific Publications (2018). ISBN: 978-981-320-856-8.  

[https://www.worldscientific.com/worldscibooks/10.1142/10407].

Book Chapters (selected):

1.  Xu Z, Ho M, Bordoloi D, Kudchodkar S, Khoshnejad M, Giron L, Zaidi F, Jeong M, Roberts CC, Park YK, Maslow J, Abdel-Mohsen M, Muthumani K. Techniques for developing and assessing immune responses induced by synthetic DNA vaccines for emerging infectious diseases, In Methods in Molecular Biology, Vaccine Design: Methods and Protocols, Vol 1. Springer Publications. 2021.

2. Bordoloi D, Kunnumakkara AB, ‘The potential of curcumin: A multitargeting agent in cancer cell chemosensitization’, In Role of Nutraceuticals in Cancer Chemosensitization, Volume 2, 1st Edition, edited by Alok C Bharti and Bharat B Aggarwal. Elsevier Publications, 2018; pp. 31-60.

3. Padmavathi G, Bordoloi D, Banik K and Kunnumakkara AB, ‘Cancer Biomarkers: Important Tools for Cancer Diagnosis and Prognosis’, In Next generation point-of-care biomedical sensors technologies for cancer diagnosisedited by Pranjal Chandra, Yen Nee Tan and Surinder P Singh. Springer Publications, 2017, pp. 1-29.

4. Roy NK, Bordoloi D, Monisha J, Anip A, Padmavathi G and Kunnumakkara AB, Cancer- an overview and molecular alterations in cancer, In Fusion Genes and Cancer, edited by Ajaikumar B Kunnumakkara, Padmavathi Ganesan and Nand Kishore Roy. World Scientific Publications. 2017, pp.1-16.

5. Padmavathi G, Bordoloi D, Monisha J, Roy NK, Harsha C and Kunnumakkara AB, ‘Recently discovered fusion genes and their implications in cancer’, In Fusion Genes and Cancer, edited by Ajaikumar B Kunnumakkara, Padmavathi Ganesan and Nand Kishor Roy.World Scientific Publications. 2017, pp. 315-348.